8 unknown, 1 completed, 1 withdrawn. 7 Phase 2, 3 Phase 3.
By phase and status
Follow SCTV01E: new trials by email Literature Review of SCTV01E trials Research Report on SCTV01E
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
SCTV01E-2, SCTV01E - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | 600 | 2023-08-10 | 2023-07-06 |
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
CoronaVac, SCTV01E - COVID-19 SARS-CoV-2 Infection | Phase 3 | Unknown | 6000 | 2023-01-25 | 2023-01-13 |
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
SCTV01E, Placebo (normal saline) - COVID-19 Pandemic | Phase 2 | Completed | 518 | 2023-01-05 | 2024-02-08 |
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
SCTV01E, Placebo - COVID-19, SARS-CoV-2 Infection | Phase 3 | Unknown | 10000 | 2022-12-26 | 2024-04-15 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
SCTV01E, mRNA-1273 - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | 300 | 2022-07-01 | 2022-04-26 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
SCTV01E, Comirnaty - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Unknown | 400 | 2022-07-01 | 2022-04-14 |
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 3 | Unknown | 1800 | 2022-05-30 | 2023-04-10 |
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | 400 | 2022-04-01 | 2022-04-11 |
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna - COVID-19, SARS-CoV-2 Infection | Phase 2 | Withdrawn | | 2022-04-01 | 2024-02-09 |
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
SCTV01E, Comirnaty - COVID-19, Sars-CoV-2 Infection | Phase 2 | Unknown | 360 | 2022-03-20 | 2022-03-02 |
Conditions studied
COVID-19 (9)
Sponsors
Sinocelltech Ltd. (10)
Countries
China (2) · United Arab Emirates (1)
Top investigators
Yu Sun (1) · Zhu Fengcai (1)
Results publications
PMID 36598621, PMID 37731938, PMID 41012186